Obesity Pharmacotherapy in a Patient With Heart Failure and CKD
A 63-year-old woman with BMI 37.8 kg/m², HFpEF (NYHA class II), stage 3b CKD (eGFR 41 mL/min/1.73 m²), and type 2 diabetes (A1c 7.8% on metformin 1000 mg twice daily) presents for weight management. Blood pressure 132/80, weight 104 kg. She has no history of pancreatitis or thyroid cancer. She has been hospitalized twice for heart failure in the past year. She asks which weight-loss medication would be 'safest for my heart and kidneys.'
1. Which pharmacologic options are best supported by outcome data for this patient, and which agents warrant caution?
Read the worked answer
Best supported.
- Semaglutide 2.4 mg has cardiovascular outcome data in obesity (SELECT) and, in the FLOW trial, kidney and cardiovascular benefit in type 2 diabetes with CKD. It is a strong candidate, though renal dosing considerations and GI tolerability during titration matter.
- Tirzepatide has robust weight and A1c efficacy and a heart-failure outcome trial in HFpEF with obesity (SUMMIT) showing benefit; it is a reasonable alternative.
- SGLT2 inhibitors are indicated for HFpEF and CKD independent of weight, and should be considered as foundational therapy alongside weight management, though their weight effect is modest.
Caution.
- Phentermine/topiramate: topiramate carries metabolic acidosis and kidney stone risk, problematic in CKD; phentermine is a stimulant.
- Naltrexone/bupropion: caution with renal impairment and accumulating metabolites.
- Orlistat: limited weight efficacy and GI side effects; not preferred.
Judgment. Prioritize agents with outcome data in her specific comorbidities, and coordinate with cardiology and nephrology rather than choosing on weight efficacy alone.
2. Her metformin dose is at the maximum and eGFR is 41. What medication adjustments and monitoring do you recommend as you start weight-loss pharmacotherapy?
Read the worked answer
Metformin. At eGFR 30–44, continue but do not initiate; maximum dose is often capped at 1000 mg/day in this range per labeling, so her 2000 mg/day should be reduced. Recheck eGFR at least every 3–6 months and hold during acute illness or contrast exposure.
Starting a GLP-1 or dual agonist.
- Titrate slowly; GI side effects can cause volume depletion and precipitate AKI in CKD.
- Monitor creatinine and electrolytes after initiation and with dose changes.
- Review diuretic dosing with cardiology as weight and volume status change.
- Counsel on hydration and sick-day rules.
Glycemic monitoring. Combining metformin with an incretin agent raises hypoglycemia risk only if insulin or a sulfonylurea is added; she is not on those, so risk is low, but A1c should be checked at 3 months.
Heart failure. Coordinate with cardiology; ensure guideline-directed HFpEF therapy (including an SGLT2 inhibitor) is optimized, and monitor for volume changes as she loses weight.
Key judgment. The medication choice is only half the answer - dose adjustment of existing therapy and monitoring for AKI during titration are where harm occurs.